Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

BACKGROUND: Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still relapse and there are currently no clear therapeutic options in post-CAR-T settings...

Descripción completa

Detalles Bibliográficos
Autores principales: Elnaggar, Muhammad, Agte, Sarita, Restrepo, Paula, Ram, Meghana, Melnekoff, David, Adamopoulos, Christos, Stevens, Mark M., Kappes, Katerina, Leshchenko, Violetta, Verina, Daniel, Jagannath, Sundar, Poulikakos, Poulikos I., Parekh, Samir, Laganà, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382834/
https://www.ncbi.nlm.nih.gov/pubmed/35978321
http://dx.doi.org/10.1186/s13045-022-01330-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382834/
https://www.ncbi.nlm.nih.gov/pubmed/35978321
http://dx.doi.org/10.1186/s13045-022-01330-3

Ejemplares similares